Clinical Trial Update: An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001 [Phase 2]

View source ↗

Summary

An extension study to further evaluate safety and tolerability of GBT440 in sickle cell disease patients who participated in the prior trial (Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• GBT440

Snippet

Sponsor: Global Blood Therapeutics | Conditions: Sickle Cell Disease | Phase 2 | Status: COMPLETED | Results posted: 2019-01-02